Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China.

Xiao Z, Hao Y, Liu B, Qian L.

Leuk Lymphoma. 2002 Sep;43(9):1763-8. Review.

PMID:
12685829
2.
3.

Interferon alpha in the treatment of chronic myelogenous leukemia.

Robak T.

Arch Immunol Ther Exp (Warsz). 1998;46(6):347-53. Review.

PMID:
9883313
4.

An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.

Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, Goldman JM, Guilhot F, Kantarjian HM, Lichtin AE, Talpaz M, Tura S.

Blood. 1999 Sep 1;94(5):1517-36. Review.

5.

Biotherapy of chronic myelogenous leukemia.

Aulitzky WE, Peschel C, Schneller F, Huber C.

Ann Hematol. 1995 Mar;70(3):113-20. Review.

PMID:
7718640
6.

Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.

Deremer DL, Ustun C, Natarajan K.

Clin Ther. 2008 Nov;30(11):1956-75. doi: 10.1016/j.clinthera.2008.11.014. Review.

PMID:
19108785
7.

Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.

Giles FJ, DeAngelo DJ, Baccarani M, Deininger M, Guilhot F, Hughes T, Mauro M, Radich J, Ottmann O, Cortes J.

Semin Oncol. 2008 Feb;35(1 Suppl 1):S1-17; quiz S18-20. doi: 10.1053/j.seminoncol.2007.12.002. Review.

PMID:
18346528
8.

Chronic myelogenous leukemia: a review.

Cortes JE, Talpaz M, Kantarjian H.

Am J Med. 1996 May;100(5):555-70. Review.

PMID:
8644769
9.

Chronic myelogenous leukemia in chronic phase.

Kurzrock R, Kantarjian H, Talpaz M.

Curr Treat Options Oncol. 2001 Jun;2(3):245-52. Review.

PMID:
12057124
10.

Progress in indirubin treatment of chronic myelocytic leukemia.

Ma MZ, Yao BY.

J Tradit Chin Med. 1983 Sep;3(3):245-8. Review. No abstract available.

PMID:
6355667
11.

Indirubin derivatives: a patent review (2010 - present).

Gaboriaud-Kolar N, Vougogiannopoulou K, Skaltsounis AL.

Expert Opin Ther Pat. 2015 May;25(5):583-93. doi: 10.1517/13543776.2015.1019865. Review.

PMID:
25887337
12.

Indirubin and Indirubin Derivatives for Counteracting Proliferative Diseases.

Blažević T, Heiss EH, Atanasov AG, Breuss JM, Dirsch VM, Uhrin P.

Evid Based Complement Alternat Med. 2015;2015:654098. doi: 10.1155/2015/654098. Epub 2015 Sep 17. Review.

Supplemental Content

Support Center